NON-ALCOHOLIC FATTY LIVER DISEASE AND CONCOMITANT PRE-DIABETES: LABORATORY CHARACTERISTIC AND INFLUENCE OF TREATMENT.

Abstract

Along with the modification of lifestyle and dietary correction, it is advisable to prescribe medication for patients with non-alcoholic fatty liver disease and concomitant pre-diabetes. Inclusion of omega-3 polyunsaturated fatty acids and essential phospholipids into the therapeutic complex leads to an improvement in the laboratory pattern of these patients because it promotes not only correction of laboratory syndromes of cytolysis and cholestasis, as well as improvement of the glycemic profile, but also corrects dyslipidemia. Comprehensive treatment with the inclusion of these medicines can serve as a good alternative to rosuvastatin, since along with the hepatoprotective effect, it is characterized by both hypolipidemic and hypotriglyceridemic effects.